Status:
COMPLETED
Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease
Lead Sponsor:
UCB Pharma
Conditions:
Crohn's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is an open-label extension study designed to measure the safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol (CDP870) in patients with moderate to severe Crohn's disease pre...
Eligibility Criteria
Inclusion
- Patients previously enrolled in C87059 (COSPAR I, NCT00349752)
Exclusion
- Subject withdrawn or discontinued from C87059 (COSPAR I, NCT00349752) study under specific conditions
- Subject who received treatment other than study medication and other than medications permitted in C87059 (COSPAR I, NCT00349752)
- Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT00356408
Start Date
January 1 2007
End Date
February 1 2010
Last Update
August 9 2018
Active Locations (63)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
Montgomery, Alabama, United States
3
La Jolla, California, United States
4
Oceanside, California, United States